製品番号: HY-136927

MSA-2

Name: MSA-2
Brand: MedChemExpress
SKU: HY-136927
Price: 100.00 USD
Availability: InStock
Rating: 5 (35 reviews)

35 Cited Publications

カスタマーレビュー

Based on 35 publication(s) in Google Scholar

MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC₅₀s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度 : 99.81%
CAS 番号: 129425-81-6
分子式: C₁₄H₁₄O₅S
分子量:294.32

保管条件:

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

MSA-2 構造式

CAS 番号: 129425-81-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体内実験

MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals^[1].
MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MC38 tumor-bearing C57BL6 mice^[1]
Dosage:

60 mg/kg
Administration:

P.o. ; s.c (50 mg/kg); single dose
Result:

PO or SC doses of MSA-2 that effectively inhibited tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor.

化学情報

CAS 番号 129425-81-6
性状 Solid
分子量 294.32
分子式 C₁₄H₁₄O₅S
Color White to light yellow
SMILES

O=C(C1=CC(C(S1)=C2)=CC(OC)=C2OC)CCC(O)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Publications (35)

All In Vivo Efficacy StudyFlow CytometryBio/Physico-chemical AssayCell Proliferation/Viability AssayCell Migration/Invasion AssayWB

Sort by:

Journal Impact Factor

Cancer Cell

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. [Abstract]

2024 May 13;42(5):850-868.e9. PMID: 38670091

MSA-2 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

Cell viability assays of isogenic NTC, Trp53 KO, and Bak/Bax KO Eμ-Myc lymphoma cell lines treated with S63845 in combination with ADU-S100 (2-10 μg/mL), MSA-2 (12-34 μM), or diABZI for 24 h.
Nature

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. [Abstract]

2023 Apr;616(7958):806-813. PMID: 36991128

MSA-2 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Apr;616(7958):806-813. [Abstract]

Athymic mice were inoculated with 1×10⁵ WT or STING knockout H2087-LCC cells via the tail vein and treated with vehicle or MSA-2 (50 mg/kg; subcutaneous injection) once weekly for 4 weeks starting two weeks after inoculation. Lungs were harvested 6 weeks after inoculation and the number of DTEs were counted.
J Hematol Oncol

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. [Abstract]

2022 Oct 8;15(1):142. PMID: 36209176

MSA-2 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]

FACS for DC maturation markers. Immature BMDCs were cultured with MSA-2 (0.3-20 μg/mL) for one day and collected for flow cytometry. MSA-2 increased CD80, CD86, H-2Kd (MHC-I), I-A/I-E (MHC-II) dose-dependent.

MSA-2 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]

The antitumor activity of MSA-2 plus YM101 in murine models. MSA-2 was administrated orally with a single dose of 50 mg/kg. Mice received equivalent mole Ab treatment on alternate days three times.
Adv Mater

Acid-Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer. [Abstract]

2023 Mar;35(10):e2209910. PMID: 36576344
Cancer Res

Dissecting FAP+ Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties. [Abstract]

2025 Apr 11. PMID: 40215177

MSA-2 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Apr 11. [Abstract]

MSA-2 (80 mg/kg, orally) strongly affected epithelial cells with a significant decrease in the proportion of Hmga²⁺ and proliferating epithelial cells.
Nat Commun

Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response. [Abstract]

2026 Feb 9;17(1):1441. PMID: 41663428
Nat Commun

Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy. [Abstract]

2025 Jul 1;16(1):5773. PMID: 40595553
Mol Cell

The mechanism of STING autoinhibition and activation. [Abstract]

2023 May 4;83(9):1502-1518.e10. PMID: 37086726
Adv Sci (Weinh)

Ginkgetin Alleviates Inflammation and Senescence by Targeting STING. [Abstract]

2025 Jan;12(2):e2407222. PMID: 39558862
Cell Death Differ

Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. [Abstract]

2024 Jan;31(1):78-89. PMID: 38007552
Mater Today Bio

In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response. [Abstract]

2024 Apr 16:26:101057. PMID: 38660475
Oncogene

Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth. [Abstract]

2026 Jun;45(23):2211-2224. PMID: 42032367
Oncogene

Synergistic reprogramming of the tumor immune microenvironment by Senecavirus A and STING agonist. [Abstract]

2026 Mar;45(9):809-822. PMID: 41673092
Cell Chem Biol

Identification of an STING inhibitor targeting the allosteric transmembrane domains. [Abstract]

2026 Apr 27:S2451-9456(26)00110-8. PMID: 42049033
BMC Med

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro. [Abstract]

2024 Mar 5;22(1):96. PMID: 38443977
Free Radic Biol Med

PGAM1-dependent VDAC1 oligomerization disrupts mitochondrial quality control to drive doxorubicin cardiotoxicity via the cGAS-STING-ferroptosis axis. [Abstract]

2026 Apr:247:71-94. PMID: 41651300
Free Radic Biol Med

Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway. [Abstract]

2023 Aug 20:205:262-274. PMID: 37330147
ACS Appl Mater Interfaces

STING Agonist Delivered by Neutrophil Membrane-Coated Gold Nanoparticles Exerts Synergistic Tumor Inhibition with Radiotherapy. [Abstract]

2024 Oct 9;16(40):53474-53488. PMID: 39316508
J Med Chem

Discovery of a New Tetrahydroquinoline-Based Chemotype for STING Inhibition with In Vivo Efficacy against Acute Kidney Injury. [Abstract]

2026 May 14;69(9):11044-11071. PMID: 41999331
Sci Signal

The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma. [Abstract]

2026 Jun 23;19(943):eaef1474. PMID: 42335217
Cell Insight

IRF1 amplifies HSV-1-triggered antiviral innate immunity in a feed-forward manner. [Abstract]

2025 May 22;4(4):100255. PMID: 40586041
Oncoimmunology

The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53-/- murine model of sarcoma. [Abstract]

2025 Dec;14(1):2534912. PMID: 40693387
OncoImmunology

Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells. [Abstract]

2022 Feb 1;11(1):2030021. PMID: 35127253
Cell Rep Methods

A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy. [Abstract]

2025 Jul 21;5(7):101106. PMID: 40669456
Int Immunopharmacol

Panobinostat suppresses cGAS-STING pathway activation and ameliorates DSS-induced colitis in mice. [Abstract]

2025 Dec 10:167:115637. PMID: 41075748
Int Immunopharmacol

USP34 regulates PIN1-cGAS-STING axis-dependent ferroptosis in cervical cancer via SUMOylation. [Abstract]

2025 Feb 6:147:113968. PMID: 39752760

MSA-2 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Feb 6:147:113968. [Abstract]

SN-011 (24, 48, or 72 h) reversed the reduction in cell proliferation caused by PIN1 knockdown in HeLa cells treated with sh-PIN1 or SiHa cells treated with pcDNA-PIN1 and MSA-2 (24, 48, or 72 h).

MSA-2 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Feb 6:147:113968. [Abstract]

Transwell assay demonstrated decreased migratory potential in sh-PIN1-treated HeLa cells, which was partially reversed by SN-011 (24 h) treatment. Conversely, MSA-2 (24 h) reduced the migration of pcDNA-PIN1-treated SiHa cells.
PLoS Pathog

HIV-1 derived oligonucleotides induce a type I IFN/STING dependent immune suppression reversible by targeting IFNARI. [Abstract]

2026 Jan 13;22(1):e1013868. PMID: 41529066
Sci Rep

Signal strength of STING activation determines cytokine plasticity and cell death in human monocytes. [Abstract]

2022 Oct 24;12(1):17827. PMID: 36280676

MSA-2 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Oct 24;12(1):17827. [Abstract]

Both diABZI (100 nM) and MSA-2 (25 µM) readily trigger the cleavage of caspase-3 and PARP-1 in monocytes. Low dose of MSA-2 (2.5 µM) and diABZI (100 nM) lead to the cleavage of gasdermin D (an indicator of pyroptosis) in monocytes.
Mol Divers

Discovery of isoindoline-2(1H)-carboxamide STING inhibitors as anti-inflammatory agents. [Abstract]

2025 Dec 11. PMID: 41379298
Bioorg Med Chem

Discovery of the thieno[2,3-b][1,4]thiazin-2(3H)-one STING inhibitors. [Abstract]

2026 Jan 16:135:118571. PMID: 41564501
Cardiovasc Intervent Radiol

Injectable Multifunctional Hydrogel Consisted of Ultrasonic Marker and Immune Adjust Agent in Liver Tumor Ablation: Animal Experiment's Study. [Abstract]

2025 Oct 31. PMID: 41174321
Chem Biodivers

Cyclopeptide Inhibitors Target the N-Terminal Tail of STING and Alleviate Autoinflammation. [Abstract]

2024 Oct;21(10):e202401253. PMID: 38997793
Biomed Res

Constant cGAS activation blunts STING signaling in DU145 prostate cancer cell line. [Abstract]

2026;47(3):89-101. PMID: 42178241
University of Rhode Island
University of Rhode Island

2024.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (169.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3977 mL

16.9883 mL

33.9766 mL

5 mM

0.6795 mL

3.3977 mL

6.7953 mL

10 mM

0.3398 mL

1.6988 mL

3.3977 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (84.94 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

All Bioinformatics Signal Pathway Related

Research Protocol for Multiple sequence alignment
Multiple sequence alignment is a computational method for arranging DNA, RNA, or protein sequences so that homologous residues or nucleotides are placed in the same columns, enabling conservation analysis, motif detection, structure prediction, phylogenetic inference, and evolutionary interpretation. MSA accuracy depends on sequence similarity, length variation, insertions and deletions, domain architecture, sequence number, and algorithm choice; therefore, no single aligner is optimal for every dataset. Commonly used MSA tools include MAFFT, MUSCLE, Clustal Omega, and T-Coffee; MAFFT provides multiple strategies for diverse alignment problems, MUSCLE emphasizes speed and accuracy, Clustal Omega scales well to large protein datasets, and T-Coffee uses consistency information to improve alignment reliability. Unresolved issues include alignment uncertainty in divergent sequences, over-alignment of unrelated regions, variable effects of automated trimming, and propagation of alignment er
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Pan BS, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369(6506):eaba6098. [Content Brief]

[2]. Liu J, et al. Identification of MSA-2: An oral antitumor non-nucleotide STING agonist. Signal Transduct Target Ther. 2021;6(1):18. Published 2021 Jan 12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3977 mL	16.9883 mL	33.9766 mL	84.9416 mL
	5 mM	0.6795 mL	3.3977 mL	6.7953 mL	16.9883 mL
	10 mM	0.3398 mL	1.6988 mL	3.3977 mL	8.4942 mL
	15 mM	0.2265 mL	1.1326 mL	2.2651 mL	5.6628 mL
	20 mM	0.1699 mL	0.8494 mL	1.6988 mL	4.2471 mL
	25 mM	0.1359 mL	0.6795 mL	1.3591 mL	3.3977 mL
	30 mM	0.1133 mL	0.5663 mL	1.1326 mL	2.8314 mL
	40 mM	0.0849 mL	0.4247 mL	0.8494 mL	2.1235 mL
	50 mM	0.0680 mL	0.3398 mL	0.6795 mL	1.6988 mL
	60 mM	0.0566 mL	0.2831 mL	0.5663 mL	1.4157 mL
	80 mM	0.0425 mL	0.2124 mL	0.4247 mL	1.0618 mL
	100 mM	0.0340 mL	0.1699 mL	0.3398 mL	0.8494 mL

Bioz

Keywords

MSA-2

35 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

MSA-2

MedChemExpress（MCE）の使用を引用している文献 MSA-2

生物活性

製品説明

体内実験

化学情報

Publications (35)

溶剤 & 溶解度

体外:

体内:

In Vivo Dissolution Calculator

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

最近チェックした製品

MSA-2

MedChemExpress（MCE）の使用を引用している文献 MSA-2

生物活性

製品説明

体内実験

化学情報

Publications (35)

溶剤 & 溶解度

体外:

体内:

In Vivo Dissolution Calculator

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

MSA-2 関連分類

HY-136927 関連分類

Bioz

Keywords

最近チェックした製品